GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
6.68
+0.72 (12.08%)
At close: Oct 9, 2026, 4:00 PM EDT
6.80
+0.12 (1.80%)
After-hours: Oct 9, 2026, 7:56 PM EDT
GT Biopharma Employees
GT Biopharma had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year. That makes GT Biopharma the 43,882nd largest employer in the world and 7,260th in the United States.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$11,380,000
Market Cap
12.05M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | -1 | -50.00% | 1 | 0 |
| Dec 31, 2023 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2022 | 2 | -6 | -75.00% | 2 | 0 |
| Dec 31, 2021 | 8 | 5 | 166.67% | 8 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 113 |
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Passage Bio | 24 |
| Daré Bioscience | 24 |
| BioLineRx | 24 |
| Lantern Pharma | 16 |
| Intensity Therapeutics | 7 |
GTBP News
- 17 hours ago - GT Biopharma registers to sell 13.5M shares of common stock for holders - TheFly
- 1 day ago - GT Biopharma Registration statement: Registration filing - Filings
- 8 days ago - GT Biopharma Proxy statement: Proxy filing - Filings
- 25 days ago - GT Biopharma trading resumes - TheFly
- 25 days ago - GT Biopharma trading halted, volatility trading pause - TheFly
- 25 days ago - GT Biopharma announces IND clearance from FDA for GTB-5550 in multiple myeloma - TheFly
- 25 days ago - GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma - GlobeNewsWire
- 4 weeks ago - GT Biopharma Transcript: Status update - Transcripts